Callan JMB Inc.

Company Overview

Business Model: Callan JMB Inc. is a vertically integrated logistics and fulfillment company specializing in thermal management logistics solutions for the life sciences industry. The company leverages proprietary packaging, information technology, and specialized cold chain logistics expertise to ensure the safety, effectiveness, and potency of products requiring continuous cryogenic or frozen temperatures. Its solutions are presented as comprehensive, reliable, and economic alternatives to traditional methods like dry ice and liquid nitrogen, serving products such as personalized medicine, cell therapies, vaccines, and bio-pharmaceuticals. Services include monitoring, recording, and archiving crucial shipment information for scientific and regulatory purposes.

Market Position: Callan JMB Inc. has established a significant market position in the emergency response industry, built on over 17 years of experience in thermal management quality assurance and control. The company serves Fortune 500 firms, the City of Chicago, NATO, the UN, and various government agencies. Its competitive strengths include a comprehensive suite of services, specialty temperature-regulating reusable packaging that reduces waste and cost, flexible emergency response offerings (e.g., 12-hour U.S. deployment, surge capacity), and an experienced team operating in highly regulated industries. While facing competition from local, regional, and national firms, no single competitor offers the full breadth of Callan JMB Inc.'s solutions.

Recent Strategic Developments: Callan JMB Inc. reorganized as a Nevada corporation on January 24, 2024, becoming a holding company for Coldchain Technology Services, LLC. The company completed an initial public offering (IPO) in February 2025, raising approximately $5.7 million in gross proceeds and $4.7 million in net proceeds. Concurrently, 1,220,000 options were issued to employees and consultants at an exercise price of $4.00 per share. The company is actively exploring expansion into new market opportunities, including glucagon-like peptide receptor-1 agonist (GLP-1) drug transport, compounding pharmacies, and the high-end food packaging industry, leveraging its Sentry monitoring system to ensure product integrity.

Geographic Footprint: Callan JMB Inc. primarily operates within North America, with a significant presence across the United States and Canada, where it offers a comprehensive range of services. The company's corporate headquarters are located at 244 Flightline Drive, Spring Branch, Texas 78070. Its facility network includes five leased properties: two in Spring Branch, Texas (10,000 sq. ft. Warehouse/Office, 7,872 sq. ft. Warehouse), two in Blanco, Texas (1,000 sq. ft. Warehouse/Office, 6,500 sq. ft. Warehouse), and one in Tigard, Oregon (4,800 sq. ft. Warehouse).

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 39.05%
• Operating Margin: -34.66%
• Net Margin: -34.94%

Investment in Growth:

• Capital Expenditures: $46,167 (2024) compared to $490,020 (2023)

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Callan JMB Inc. has never declared or paid cash dividends and currently intends to retain all future earnings to finance business operations and expansion. No dividends are expected in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $2,097,945 (as of December 31, 2024)
• Total Debt: $0 (as of December 31, 2024), down from $98,809 (as of December 31, 2023)
• Net Cash Position: $2,097,945 (as of December 31, 2024)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Lease liabilities mature as follows: $342,065 in 2025, $187,600 in 2026, $185,100 in 2027, $185,100 in 2028, and $185,094 in 2029.

Cash Flow Generation:

• Operating Cash Flow: $540,353 (2024)
• Free Cash Flow: $494,186 (2024)
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Callan JMB Inc. operates a vertically integrated logistics and fulfillment model focused on thermal management solutions. Its system employs advanced predictive technology to ensure product integrity, safety, effectiveness, and potency for time-sensitive biological materials. The company offers comprehensive, reliable, and economic alternatives to traditional frozen shipping methods. Key service offerings include emergency preparedness and response (featuring 12-hour U.S. deployment and surge capacity), specialty temperature-regulating reusable packaging, and fulfillment services supported by a technical service center. The company also provides the ability to monitor, record, and archive crucial shipment information for scientific and regulatory compliance.

Supply Chain Architecture: The company's supply chain relies on third-party suppliers for essential equipment and materials, including refrigeration, storage, and electrical components. The supplier base for cold chain and food processing/warehouse equipment is relatively consolidated. For transportation, Callan JMB Inc. utilizes a fragmented market of third-party service providers.

Key Suppliers & Partners:

• Shipping Services: FedEx, DHL, UPS (strategic alliances for seamless, end-to-end shipping solutions).
• Packaging: Obtains specialty temperature-regulating packaging from third-party suppliers.

Facility Network:

• Headquarters: 244 Flightline Drive, Spring Branch, Texas 78070 (10,000 sq. ft. Warehouse/Office).
• Warehousing & Distribution:
  • 10130 SW North Dakota St., Tigard, Oregon 97223 (4,800 sq. ft. Warehouse).
  • 1500 4th St., Unit #6, Blanco, Texas 78606 (1,000 sq. ft. Warehouse/Office).
  • 210 Kestral Drive, Spring Branch, Texas 78070 (7,872 sq. ft. Warehouse).
  • 16025 Farm to Market 32, Blanco, Texas 78606 (6,500 sq. ft. Warehouse).

Operational Metrics: Not disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Callan JMB Inc. aims to expand its market presence by leveraging its core competitive strengths, diversifying its customer base, and growing its service lines. The strategy includes cross-selling its broad range of solutions to existing customers and expanding into new market opportunities. The company intends to broaden strategic alliances with domestic and international shipping service providers and other solutions providers in the life sciences industry.

Customer Portfolio: Callan JMB Inc. serves a diverse customer base primarily within the life sciences industry, including entities involved with personalized medicine, cell therapies, vaccines, and diagnostic materials. In 2024, governmental customers accounted for $3,938,480 of revenue, while non-governmental customers contributed $2,624,932. The company faces significant customer concentration, with its top three customers (Customer 1, Customer 2, and Customer 3) collectively accounting for approximately 81.4% of total revenue in 2024. Customer 1 has long-term agreements expiring in 2026 and 2029. A customer representing approximately $4,000,000 of 2023 revenue temporarily suspended ordering in 2024, though continued business is anticipated.

Geographic Revenue Distribution: The company's customer base and operations are primarily concentrated in North America, specifically the United States and Canada. No further disaggregation of revenue by specific geographic regions or countries is provided.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: Callan JMB Inc. operates in a rapidly growing segment of the logistics industry focused on temperature-sensitive packaging and shipping of biological materials. Expenditures for "value-added" packaging for frozen transport have been increasing and are expected to continue to grow due to globalization and the introduction of pharmaceutical products requiring cryogenic temperatures. This trend necessitates greater reliance on passively controlled temperature transport systems and is expected to drive more comprehensive tracking and validation of shipping temperatures through evolving industry standards and regulations. Key growth markets include cell-based therapies, gene and stem cell biotechnology, vaccine production, commercial and specialty drug distribution, clinical trials, and GLP-1 drug transport.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Callan JMB Inc. faces robust competition from local, regional, and national firms. Specific competitors include some cryogenic equipment manufacturers and shippers offering solutions for storing and transporting cryogenic liquid and gases, as well as specialty couriers providing dry ice transportation and temperature-controlled packaging solutions. However, no single competitor directly offers the full suite of Callan JMB Inc.'s integrated solutions.

Emerging Competitive Threats: The company anticipates potential threats from new market entrants, disruptive technologies, and alternative solutions. Competitors with greater resources may develop and expand their networks and product offerings more quickly, dedicate more resources to marketing and sales, and adopt aggressive pricing strategies.

Competitive Response Strategy: Callan JMB Inc.'s strategy involves leveraging its core competitive strengths, developing and maintaining diversified customer relationships, and continuously growing its service lines. The company emphasizes the breadth of its services, quality, responsiveness, customer service, information technologies, safety, and cost-effectiveness. Strategic initiatives include cross-selling solutions, expanding into new market opportunities (e.g., GLP-1 drug transport, high-end food packaging), implementing cost, pricing, and productivity initiatives, and fostering innovation through technology.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company experienced a significant revenue decrease in 2024, partly due to the waning of the COVID-19 pandemic and diminished demand for emergency preparedness services from state and local governments. Technology Disruption: There is a risk that competitors may develop comparable, superior, or less costly products and services. Without timely introduction of new products and enhancements, the company's offerings could become obsolete, impacting revenue and operating results. Customer Concentration: A substantial portion of the company's revenue is derived from a few key customers, with the top three accounting for 81.4% of total revenue in 2024. The loss of one or more of these major customers could materially adversely affect the business and financial condition.

Operational & Execution Risks

Supply Chain Vulnerabilities: Callan JMB Inc. relies on third-party suppliers for critical equipment and materials, including refrigeration and storage components. The supplier base for cold chain equipment is relatively consolidated, while the market for third-party transportation services is fragmented. Any significant reduction in availability or increase in costs of these inputs could adversely affect operations and profitability. Product & Service Defects: The company's products and services must meet stringent requirements. Undetected errors or defects, particularly in new offerings or when used in sensitive applications like human reproductive medicine, could lead to reputational damage, lost revenues, increased service costs, litigation, and product recalls. Shipping Delays: Reliance on third-party shipment and carrier services exposes the company to risks of delays or disruptions due to natural disasters, adverse weather, or carrier error, which could harm temperature-sensitive biological materials and lead to customer dissatisfaction or liability. Capital Intensive Business: The company's rent-to-rent model and operational expansion require significant upfront and ongoing capital outlays for warehouse sourcing, renovation, and maintenance. Inability to collect service fees in a timely manner or a mismatch in service agreement terms could adversely affect financial condition. Growth Management: Rapid growth and development require continuous enhancement of financial and management controls, information systems, cost control, marketing, and the ability to attract and retain qualified personnel. Failure to effectively manage growth could materially and adversely affect the business.

Financial & Regulatory Risks

Liquidity & Capital: The business is capital intensive, and its ability to remain competitive and grow depends on cash flow from operations and access to capital. The company may need to raise substantial additional capital through equity offerings, debt financings, or strategic collaborations, which could result in dilution for stockholders or restrictive covenants. Regulatory Compliance: Callan JMB Inc. is subject to extensive federal, state, and local regulations, including those from the FDA, USDA, CDC, OSHA, DOT, IATA, and ICAO, governing product safety, storage, distribution, and employee safety. Compliance is costly and time-consuming, and failure to adhere to regulations could result in fines, penalties, operational limitations, product recalls, or loss of licenses. Tax Risks: The company is subject to income taxes and various non-income-based taxes across multiple jurisdictions. Significant judgment is required in determining tax provisions, and changes in tax laws or adverse outcomes from tax audits could negatively affect financial results. Legal Proceedings: The company may be involved in legal proceedings and claims in the ordinary course of business. A recent demand letter alleging breach of a Customer Service Agreement was settled for $240,800 in February 2025. Litigation, including intellectual property claims, could result in substantial expenses and disrupt business.

Geopolitical & External Risks

Cybersecurity: The company relies on critical information systems, including its Sentry platform, for order automation, customs documentation, and shipment monitoring. These systems are vulnerable to cyberattacks, data breaches, and other disruptions. A successful cyber incident could lead to costly investigations, business disruption, reputational damage, and significant financial liabilities, potentially exceeding insurance coverage. Management Experience: The management team has limited experience managing a public company, which may divert attention from day-to-day business operations. Controlled Company Status: Wayne Williams and Dr. David J. Croyle collectively control 70.6% of the voting power of the outstanding common stock, making Callan JMB Inc. a "controlled company" under Nasdaq rules. This status allows the company to elect not to comply with certain corporate governance requirements, potentially reducing protections for other stockholders.

Innovation & Technology Leadership

Research & Development Focus: Callan JMB Inc. emphasizes fostering innovation through technology, integrating advanced technologies into its operations and customer solutions. The core focus areas include thermal management logistics, leveraging proprietary packaging, information technology, and specialized cold chain know-how. The company aims to utilize artificial intelligence and predictive technology to enhance productivity and ensure product safety and efficiency.

Core Technology Areas:

• Thermal Management Logistics: Utilizes proprietary packaging and specialized cold chain logistics know-how.
• Predictive Technology: Employs advanced predictive technology to guarantee product safety, effectiveness, and potency.
• Monitoring: The Sentry monitoring system tracks temperature, humidity, and location to ensure the physical material integrity of packages.
• Inventory Management Software: Proprietary software, Ship2Q®, is used for scalable ordering, inventory, pick, pack, fulfillment, tracking, and recovery.

Innovation Pipeline: The company plans to expand its business to include support for GLP-1 drug transport, compounding pharmacies, and high-end food packaging, leveraging its Sentry monitoring system to minimize spoilage and contamination risks.

Intellectual Property Portfolio: The company mentions proprietary packaging, information technology, and proprietary software (Ship2Q® and Sentry monitoring) as key assets. No specific details on patent holdings, licensing programs, or IP litigation are provided.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company depends on the continued high performance of its executive team and other employees. The loss of key executives or an inability to attract and retain highly skilled employees could materially harm the business. Employment agreements are in place for key executives, including severance provisions for certain termination events or change in control.

Board Composition: The Board of Directors includes Wayne Williams (CEO, President, Chairman) and Eric L. Kash (Executive Vice President, Director). Independent directors, appointed effective February 4, 2025, include Mark Meller, Liberty Smith Duke, and Senator Gerald Dial. The Board has determined that Messrs. Meller and Dial and Ms. Duke are independent under SEC and Nasdaq rules. Mark Meller qualifies as an "audit committee financial expert." Wayne Williams and Dr. David J. Croyle are brothers-in-law.

Board Committees:

• Audit Committee: Mark Meller (Chairman), Liberty Smith Duke, Gerald Dial. Oversees accounting, financial reporting, internal controls, and independent registered public accounting firm.
• Compensation Committee: Liberty Smith Duke (Chairman), Mark Meller, Gerald Dial. Reviews and recommends compensation for directors and executive officers, administers equity incentive plans.
• Nominating and Corporate Governance Committee: Senator Gerald Dial (Chairman), Mark Meller, Liberty Smith Duke. Identifies and evaluates director candidates, considers board and committee composition, and reviews executive officer succession plans.

Director Compensation: Independent directors receive a cash fee of $6,250 per fiscal quarter and are awarded 6,250 shares of common stock each fiscal quarter, in addition to participation in an equity incentive plan.

Human Capital Strategy

Workforce Composition: As of the date of the 10-K filing, Callan JMB Inc. has 26 employees, comprising 10 full-time employees and 12 part-time or contractual/seasonal employees. The company also engages independent contractors as needed.

Talent Management: The company's future success relies on its ability to identify, hire, develop, motivate, retain, and integrate highly skilled personnel across all areas of the organization. Acquisition & Retention: Not explicitly detailed beyond the general need to attract and retain qualified management personnel. Employee Value Proposition: Not explicitly detailed.

Diversity & Development: Not explicitly detailed.

Culture & Engagement: Employee and customer safety is a top priority. The company periodically reviews and assesses its policies, practices, and procedures to create a safer work environment.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Not explicitly detailed. Carbon Neutrality: Not explicitly detailed. Renewable Energy: Not explicitly detailed.

Supply Chain Sustainability: Callan JMB Inc. is committed to environmental sustainability, primarily through its utilization of reusable packaging systems and a leasing model, which helps reduce waste and costs compared to traditional, single-use packaging.

Social Impact Initiatives: Not explicitly detailed.

Business Cyclicality & Seasonality

Demand Patterns: Callan JMB Inc.'s operations are expected to vary seasonally, with revenue typically highest in the third and fourth calendar quarters and lowest in the first and second calendar quarters. These seasonal fluctuations are influenced by weather conditions and general economic activity.

Planning & Forecasting: Operating expenses may be higher during winter months due to periodic adverse weather conditions, which can slow service delivery and result in increased labor and operational costs.

Regulatory Environment & Compliance

Regulatory Framework: Callan JMB Inc. is subject to extensive federal, state, and local regulations. Industry-Specific Regulations: These include the Food, Drug and Cosmetic Act of 1938, the Nutrition Labeling and Education Act of 1990, the USDA HACCP Mega-Reg of 1996, the Public Health Security and Bioterrorism Preparedness & Response Act of 2002, and the Food Safety Modernization Act of 2011. The company must comply with rules and regulations from the FDA, USDA, and various state and local agencies. It holds Wholesale Drug Distributor, DEV (device distributor), and 3PL (third party logistics) licenses, is VAWD Accredited by the National Association Boards of Pharmacy, and complies with USP 1079/1083, FDA 21 CFR Part 11/210/211 & 820, and ICHQ8/Q10. Employee Safety Regulations: The company adheres to regulations issued pursuant to the Occupational Safety and Health Act. Environmental Regulations: Callan JMB Inc. is subject to federal, state, and local environmental regulations governing discharges to air and water, management of hazardous substances, waste disposal, and remediation. Shipping Regulations: Shipments using the company's solutions must comply with requirements from the Centers for Disease Control, Occupational Safety and Health Organization, Department of Transportation, International Air Transport Association, and International Civil Aviation Organization. The company's data logger may also be subject to regulation and certification by the FDA, Federal Communications Commission, and Federal Aviation Administration.

Trade & Export Controls: As a global operator, the company is subject to complex foreign and U.S. laws, including the U.S. Foreign Corrupt Practices Act, anti-competition regulations, and sanctions imposed by the U.S. Office of Foreign Assets Control.

Legal Proceedings: In May 2024, the company received a demand letter alleging breach of a Customer Service Agreement with a vendor, claiming $507,573. This matter was settled in February 2025 for $240,800, which was paid on February 26, 2025.

Tax Strategy & Considerations

Tax Profile: Callan JMB Inc. reorganized from a Texas limited liability company (pass-through entity) to a Nevada C corporation on February 14, 2024. Consequently, it is now subject to federal, state, and local income taxes, as well as non-income-based taxes such as payroll, sales, use, value-added, net worth, property, and goods and services taxes. The effective tax rate was 1% for both 2024 and 2023, influenced by its prior pass-through status and a full valuation allowance against deferred tax assets in 2024. As of December 31, 2024, the company has federal net operating loss (NOL) carryforwards of $2,354,213 (subject to an 80% limitation on future taxable income) and state NOL carryforwards of $255,646 (expiring after 20 years). A full valuation allowance has been provided against deferred tax assets due to uncertainty regarding their realizability.

Insurance & Risk Transfer

Risk Management Framework: Callan JMB Inc. maintains minimum insurance coverage to protect against a broad range of risks, at levels considered appropriate and consistent with industry practice. The objective is to minimize financial loss at a reasonable cost. The company also holds third-party insurance coverage for cybersecurity risks. However, there is no assurance that coverage will be adequate for all potential liabilities, including data security incidents or indemnification claims, or that it will be available on economically reasonable terms in the future.